CY2013029PI2 - NEW INSULIN DERIVATIVES - Google Patents

NEW INSULIN DERIVATIVES

Info

Publication number: CY2013029PI2
Authority: CY; Cyprus
Prior art keywords: insulin derivatives; new insulin; new; derivatives; insulin
Prior art date: 2003-08-05

Application number

CY2013029C

Other languages

Greek (el)

Original Assignee

Novo Nordisk A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-05

Filing date

2013-07-08

Publication date

2015-11-04

2013-07-08 Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S

2015-11-04 Publication of CY2013029PI1 publication Critical patent/CY2013029PI1/en

2015-11-04 Publication of CY2013029PI2 publication Critical patent/CY2013029PI2/en

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

CY2013029C 2003-08-05 2013-07-08 NEW INSULIN DERIVATIVES CY2013029PI2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA200301129		2003-08-05
US49545103P	2003-08-14	2003-08-14
EP04739008A EP1660531A2 (en)	2003-08-05	2004-07-22	Novel insulin derivatives

Publications (2)

Publication Number	Publication Date
CY2013029PI1 CY2013029PI1 (en)	2015-11-04
CY2013029PI2 true CY2013029PI2 (en)	2015-11-04

Family

ID=34117520

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
CY20131100259T CY1113850T1 (en)	2003-08-05	2013-03-28	NEW INSULIN PRODUCERS
CY2013027C CY2013027PI1 (en)	2003-08-05	2013-07-04	NEW INSULIN DERIVATIVES
CY2013029C CY2013029PI2 (en)	2003-08-05	2013-07-08	NEW INSULIN DERIVATIVES
CY2013029C CY2013029I2 (en)	2003-08-05	2023-12-28	NEW INSULIN DERIVATIVES
CY2013027C CY2013027I1 (en)	2003-08-05	2024-01-31	NEW INSULIN DERIVATIVES

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
CY20131100259T CY1113850T1 (en)	2003-08-05	2013-03-28	NEW INSULIN PRODUCERS
CY2013027C CY2013027PI1 (en)	2003-08-05	2013-07-04	NEW INSULIN DERIVATIVES

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
CY2013029C CY2013029I2 (en)	2003-08-05	2023-12-28	NEW INSULIN DERIVATIVES
CY2013027C CY2013027I1 (en)	2003-08-05	2024-01-31	NEW INSULIN DERIVATIVES

Country Status (18)

Country	Link
US (3)	US7615532B2 (en)
EP (3)	EP2107069B1 (en)
JP (1)	JP4463814B2 (en)
KR (1)	KR101159559B1 (en)
AU (2)	AU2004261353B2 (en)
BE (2)	BE2013C035I2 (en)
BR (1)	BRPI0413276B8 (en)
CA (1)	CA2531988C (en)
CY (5)	CY1113850T1 (en)
FR (2)	FR13C0035I2 (en)
HU (1)	HUS1300033I1 (en)
IL (1)	IL172980A (en)
LU (2)	LU92213I2 (en)
MX (1)	MXPA06001283A (en)
NO (5)	NO340925B1 (en)
PL (1)	PL2107069T3 (en)
RU (1)	RU2518460C2 (en)
WO (1)	WO2005012347A2 (en)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1648933T1 (en) *	2003-07-25	2010-01-29	Conjuchem Biotechnologies Inc	Long lasting insulin derivatives and methods thereof
AU2004261353B2 (en)	2003-08-05	2009-12-10	Novo Nordisk A/S	Novel insulin derivatives
ES2435522T3 (en) *	2005-02-02	2013-12-20	Novo Nordisk A/S	Insulin derivatives
WO2006082204A1 (en) *	2005-02-02	2006-08-10	Novo Nordisk A/S	Insulin derivatives
EP1969004B1 (en)	2005-12-28	2011-08-10	Novo Nordisk A/S	Compositions comprising an acylated insulin and zinc and method of making the said compositions
JP5202338B2 (en) *	2006-02-27	2013-06-05	ノボ・ノルデイスク・エー／エス	New insulin derivatives
WO2007104736A2 (en) *	2006-03-13	2007-09-20	Novo Nordisk A/S	Acylated single chain insulin
WO2007127236A2 (en)	2006-04-28	2007-11-08	Acrymed, Inc.	Antimicrobial site dressings
AU2007247109B2 (en)	2006-05-09	2012-03-15	Novo Nordisk A/S	Insulin derivative
CN101437849B (en) *	2006-05-09	2015-09-30	诺沃-诺迪斯克有限公司	Insulin derivatives
WO2007128815A1 (en)	2006-05-09	2007-11-15	Novo Nordisk A/S	Insulin derivative
JP5097900B2 (en) *	2006-06-27	2012-12-12	独立行政法人物質・材料研究機構	Method for producing active ester of organic acid or derivative thereof
CN101573133B (en) *	2006-07-31	2014-08-27	诺沃-诺迪斯克有限公司	PEGylated, extended insulins
CN101541830A (en)	2006-09-22	2009-09-23	诺沃-诺迪斯克有限公司	Protease resistant insulin analogues
WO2008132224A2 (en)	2007-04-30	2008-11-06	Novo Nordisk A/S	Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
AU2008257505B2 (en) *	2007-06-01	2013-05-16	Novo Nordisk A/S	Stable non-aqueous pharmaceutical compositions
EP2514406A1 (en)	2007-06-01	2012-10-24	Novo Nordisk A/S	Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
JP5552046B2 (en) *	2007-06-13	2014-07-16	ノボ・ノルデイスク・エー／エス	Pharmaceutical preparation containing an insulin derivative
AU2008288413B2 (en) *	2007-08-15	2013-09-26	Novo Nordisk A/S	Insulin analogues with an acyl and aklylene glycol moiety
WO2009022006A1 (en)	2007-08-15	2009-02-19	Novo Nordisk A/S	Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
CN101157725B (en) *	2007-10-24	2012-07-25	中国药科大学	Preparation method of human insulin analogue and usage thereof
ES2543393T3 (en)	2007-11-08	2015-08-18	Novo Nordisk A/S	Insulin derivative
CN101861333A (en)	2007-11-16	2010-10-13	诺沃-诺迪斯克有限公司	Pharmaceutical composition comprising a GLP-1 peptide or exendin-4 peptide and a basal insulin peptide
CN101970477B (en)	2008-03-14	2014-12-31	诺沃-诺迪斯克有限公司	Protease-stabilized insulin analogues
HUE032284T2 (en)	2008-03-18	2017-09-28	Novo Nordisk As	Protease stabilized, acylated insulin analogues
CN102149411A (en)	2008-09-12	2011-08-10	诺沃—诺迪斯克有限公司	Method for acylation of peptide or protein
CN102202683A (en)	2008-10-30	2011-09-28	诺沃-诺迪斯克有限公司	Treating diabetes melitus using insulin injections with less than daily injection frequency
CN102361647B (en)	2009-01-23	2018-02-16	诺沃-诺迪斯克有限公司	FGF21 derivatives and its application with albumin combination agent A B C D E
WO2011051312A1 (en)	2009-10-30	2011-05-05	Novo Nordisk A/S	Derivatives of cgrp
BR112012016853A2 (en) *	2010-01-12	2017-10-17	Novo Nordisk As	"pharmaceutical compositions for oral administration of insulin peptides".
ES2582590T3 (en)	2010-02-16	2016-09-13	Novo Nordisk A/S	Purification method
US9234192B2 (en)	2010-02-16	2016-01-12	Novo Nordisk A/S	Conjugated proteins
AU2011252127B2 (en)	2010-05-10	2014-02-20	Novo Nordisk A/S	Process for the preparation of insulin-zinc complexes
US8748570B2 (en)	2010-05-25	2014-06-10	Syngene Limited	Insulin analogues
CA2802510A1 (en)	2010-06-23	2011-12-29	Novo Nordisk A/S	Insulin derivatives containing additional disulfide bonds
EP2585484A1 (en)	2010-06-23	2013-05-01	Novo Nordisk A/S	Insulin analogues containing additional disulfide bonds
EP2585483A1 (en)	2010-06-23	2013-05-01	Novo Nordisk A/S	Human insulin containing additional disulfide bonds
JP2013540771A (en)	2010-10-15	2013-11-07	ノヴォノルディスクアー／エス	Novel N-terminally modified insulin derivative
KR20130139297A (en) *	2010-10-27	2013-12-20	노보 노르디스크 에이/에스	Treating diabetes melitus using insulin injections administered with varying injection intervals
DK2632478T3 (en) *	2010-10-27	2019-10-07	Novo Nordisk As	TREATMENT OF DIABETES MELITUS USING INSULIN INJECTIONS SUBMITTED AT VARIOUS INJECTION INTERVALS
WO2012080320A1 (en)	2010-12-14	2012-06-21	Novo Nordisk A/S	Fast-acting insulin in combination with long-acting insulin
JP2014510516A (en)	2011-02-15	2014-05-01	ノヴォノルディスクアー／エス	Long acting IL-1 receptor antagonist
RU2013145013A (en) *	2011-03-28	2015-05-10	Ново Нордиск А/С	NEW GLUCAGON ANALOGUES
CN103458873B (en)	2011-04-14	2016-04-13	诺沃—诺迪斯克有限公司	For the aminoacid of the fatty-acylation of oral peptide delivery
EP2720711A1 (en)	2011-06-15	2014-04-23	Novo Nordisk A/S	Multi substituted insulins
MX354705B (en) *	2011-09-23	2018-03-16	Novo Nordisk As	Novel glucagon analogues.
CN104788556A (en) *	2011-12-15	2015-07-22	上海恒瑞医药有限公司	Human insulin analog and acylated derivative thereof
WO2013093009A1 (en)	2011-12-21	2013-06-27	Novo Nordisk A/S	N -terminally modified insulin derivatives
EP2836508B1 (en)	2012-04-11	2016-06-29	Novo Nordisk A/S	Insulin formulations
US20160031962A1 (en) *	2012-04-20	2016-02-04	Kleomenis K. Barlos	Solid phase peptide synthesis of insulin using side chain achored lysine
EP2844274B1 (en)	2012-05-01	2019-03-20	Novo Nordisk A/S	Pharmaceutical composition
WO2014009316A1 (en)	2012-07-09	2014-01-16	Novo Nordisk A/S	Novel use of insulin derivatives
UA116217C2 (en)	2012-10-09	2018-02-26	Санофі	Exendin-4 derivatives as dual glp1/glucagon agonists
JP6285447B2 (en)	2012-10-17	2018-02-28	ノヴォノルディスクアー／エス	Fatty acylated D-amino acids for oral peptide delivery
HUE035803T2 (en)	2012-12-21	2018-05-28	Sanofi Sa	Dual glp1/gip or trigonal glp1/gip/glucagon agonists
US20160296602A1 (en) *	2013-03-20	2016-10-13	Novo Nordisk A/S	Dosing Regimen
BR112015025464A2 (en)	2013-04-18	2017-10-10	Novo Nordisk As	stable, prolonged glp-1 / glucagon receptor coagonists for medical use
EP2991672A1 (en)	2013-04-30	2016-03-09	Novo Nordisk A/S	Novel administration regime
GB201315335D0 (en)	2013-08-29	2013-10-09	Of Singapore	Amino diacids containing peptide modifiers
CA2926701A1 (en)	2013-10-07	2015-04-16	Novo Nordisk A/S	Novel derivative of an insulin analogue
FR3013049B1 (en)	2013-11-14	2015-11-13	You-Ping Chan	ANALOGUE OF INSULIN GLARGINE
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
TW201609797A (en)	2013-12-13	2016-03-16	賽諾菲公司	Dual GLP-1/glucagon receptor agonists
AR100306A1 (en)	2014-02-18	2016-09-28	Novo Nordisk As	GLUCAGON ANALOGS STABLE AND USE FOR THE TREATMENT OF HYPOGLUCEMIA
AR099569A1 (en)	2014-02-28	2016-08-03	Novo Nordisk As	INSULIN DERIVATIVES AND THE MEDICAL USES OF THESE
TW201625668A (en)	2014-04-07	2016-07-16	賽諾菲公司	Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625670A (en)	2014-04-07	2016-07-16	賽諾菲公司	Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625669A (en)	2014-04-07	2016-07-16	賽諾菲公司	Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
JP2017525656A (en)	2014-06-04	2017-09-07	ノヴォノルディスクアー／エス	GLP-1 / glucagon receptor co-agonist for medical use
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (en)	2015-06-05	2017-09-27	Sanofi Sa	PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
TW201706291A (en)	2015-07-10	2017-02-16	賽諾菲公司	New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
EP3341401A1 (en)	2015-08-25	2018-07-04	Novo Nordisk A/S	Novel insulin derivatives and the medical uses hereof
CN108368163A (en)	2015-08-25	2018-08-03	诺和诺德股份有限公司	Novel insulin derivates and its medical usage
US10815287B2 (en)	2016-08-02	2020-10-27	Jiangsu Hengrui Medicine Co., Ltd.	Acylated derivative of human insulin or analogue thereof
WO2018096164A1 (en)	2016-11-28	2018-05-31	Novo Nordisk A/S	Insulin degludec for treating diabetes
EP3544683A1 (en)	2016-11-28	2019-10-02	Novo Nordisk A/S	Insulin degludec in cardiovascular conditions
MA46890A (en)	2016-11-28	2021-04-28	Novo Nordisk As	INSULIN DEGLUDEC FOR IMPROVEMENT OF GLYCEMIC CONTROL AND REDUCTION OF COMPLICATIONS OF ACUTE AND LONG-TERM DIABETES
ES2886837T3 (en)	2016-12-16	2021-12-21	Novo Nordisk As	Pharmaceutical compositions containing insulin
JOP20190273A1 (en)	2017-05-26	2019-11-24	Lilly Co Eli	Insulin treated with basil complex
US20210032307A1 (en)	2018-02-09	2021-02-04	Jiangsu Hengrui Medicine Co., Ltd.	Codon optimized precursor gene and signal peptide gene of human insulin analogue
KR20210016400A (en)	2018-05-24	2021-02-15	지앙수 헨그루이 메디슨 컴퍼니 리미티드	Method for producing a precursor of recombinant human insulin or its analog
CN112313755B (en)	2018-06-26	2024-05-28	诺和诺德股份有限公司	System that provides dosage recommendations for basal insulin titration
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
KR102666154B1 (en)	2018-08-08	2024-05-20	주식회사 대웅제약	Long-acting Insulin Analog and Derivatives Thereof
KR20200080747A (en)	2018-12-27	2020-07-07	주식회사 폴루스	An Enzymatic Conversion Composition for Producing Insulin from Proinsulin and a Method for Producing Insulin from Proinsulin Using the Same
KR20200080748A (en)	2018-12-27	2020-07-07	주식회사 폴루스	A Method for Purifying Proinsulin Using Anion Exchange Chromatography
CN114096269B (en)	2019-07-12	2024-06-11	诺和诺德股份有限公司	High-concentration insulin preparations
TWI844709B (en)	2019-07-31	2024-06-11	美商美國禮來大藥廠	Relaxin analogs and methods of using the same
BR112022013009A2 (en)	2019-12-30	2022-09-06	Gan & Lee Pharmaceuticals Co Ltd	INSULIN DERIVATIVES, PHARMACEUTICAL COMPOSITION, INSULIN DERIVATIVE USE AND METHODS TO TREAT OR PREVENT DIABETES, TO INCREASE THE CAPACITY OF AN INSULIN DERIVATIVE, AND TO INCREASE THE POTENCY OF AN INSULIN DERIVATIVE
WO2021231676A1 (en)	2020-05-15	2021-11-18	Eli Lilly And Company	Extended time action acylated insulin compounds
CN113773398B (en) *	2020-06-10	2023-05-23	宁波鲲鹏生物科技有限公司	De-glu insulin derivative and application thereof
EP4299057A1 (en)	2022-06-30	2024-01-03	Adocia	Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en)	2021-11-15	2023-05-17	Adocia	Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4433093A1 (en)	2021-11-15	2024-09-25	Adocia	Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023143458A1 (en)	2022-01-28	2023-08-03	甘李药业股份有限公司	Acylated insulin
EP4299071A1 (en)	2022-07-01	2024-01-03	Adocia	Compositions comprising a peptide or a protein and an acylated amino acid
WO2025098457A1 (en)	2023-11-07	2025-05-15	甘李药业股份有限公司	Acylated insulin for reducing blood glucose
WO2025104600A1 (en) *	2023-11-15	2025-05-22	Ambio, Inc.	Insulin analogs for the treatment of human metabolic disorder and disease
US20260216297A1 (en) *	2024-10-29	2026-07-30	Portal Diabetes Inc.	Stabilized formulations of insulin and insulin analogs

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1212679B (en)	1957-08-03	1966-03-17	Novo Terapeutisk Labor As	Process for the preparation of insulin solutions
GB1042194A (en)	1962-04-30	1966-09-14	Olin Mathieson	Insulin preparations
US3528960A (en)	1968-10-07	1970-09-15	Lilly Co Eli	N-carboxyaroyl insulins
US3868358A (en) *	1971-04-30	1975-02-25	Lilly Co Eli	Protamine-insulin product
GB1492997A (en)	1976-07-21	1977-11-23	Nat Res Dev	Insulin derivatives
JPS5767548A (en)	1980-10-14	1982-04-24	Shionogi & Co Ltd	Insulin analog and its preparation
FI78616C (en) *	1982-02-05	1989-09-11	Novo Industri As	Process for preparing an infused stabilized insulin solution having an elevated zinc content
PH25772A (en)	1985-08-30	1991-10-18	Novo Industri As	Insulin analogues, process for their preparation
NZ222907A (en)	1986-12-16	1990-08-28	Novo Industri As	Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5605884A (en) *	1987-10-29	1997-02-25	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Factor VIII formulations in high ionic strength media
US4877608A (en)	1987-11-09	1989-10-31	Rorer Pharmaceutical Corporation	Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (en)	1988-04-05	1989-10-11	Kodama Kk	Insulin derivative and use thereof
DE3827533A1 (en) *	1988-08-13	1990-02-15	Hoechst Ag	PHARMACEUTICAL PREPARATION FOR TREATING THE DIABETES MELLITUS
HUT56857A (en)	1988-12-23	1991-10-28	Novo Nordisk As	Human insulin analogues
IL93282A (en)	1989-02-09	1995-08-31	Lilly Co Eli	Insulin analogs
IT1240314B (en)	1989-09-28	1993-12-07	Immunobiology Research Institutes, Inc.	STABILIZED AQUEOUS FORMULATIONS OF SMALL PEPTIDES.
US5382574A (en) *	1989-12-21	1995-01-17	Novo Nordisk A/S	Insulin preparations containing nicotinic acid or nicotinamide
DK45590D0 (en)	1990-02-21	1990-02-21	Novo Nordisk As
JP3193398B2 (en)	1991-07-23	2001-07-30	サンデン株式会社	Showcase
DE10399015I1 (en)	1991-12-20	2012-05-03	Novo Nordisk As	Stabilized pharmaceutical formulation containing growth hormone and histidine
NZ273285A (en)	1993-09-17	1997-10-24	Novo Nordisk As	Insulin derivatives and compositions thereof
US6869930B1 (en) *	1993-09-17	2005-03-22	Novo Nordisk A/S	Acylated insulin
US6011007A (en) *	1993-09-17	2000-01-04	Novo Nordisk A/S	Acylated insulin
US5652216A (en)	1994-05-26	1997-07-29	Novo Nordisk A/S	Pharmaceutical preparation
WO1996010417A1 (en)	1994-10-04	1996-04-11	Novo Nordisk A/S	PREPARATIONS CONTAINING AspB28 HUMAN INSULIN AND NICOTINAMIDE
US5646242A (en) *	1994-11-17	1997-07-08	Eli Lilly And Company	Selective acylation of epsilon-amino groups
US5830999A (en) *	1995-01-26	1998-11-03	Regents Of The University Of California	Stabilization of insulin through ligand binding interations
CA2215694A1 (en)	1995-03-17	1996-09-26	Novo Nordisk A/S	Insulin derivatives
US6251856B1 (en) *	1995-03-17	2001-06-26	Novo Nordisk A/S	Insulin derivatives
CA2226575C (en)	1995-07-27	2011-10-18	Genentech, Inc.	Stabile isotonic lyophilized protein formulation
US6451970B1 (en) *	1996-02-21	2002-09-17	Novo Nordisk A/S	Peptide derivatives
US5898267A (en) *	1996-04-10	1999-04-27	Mcdermott; Kevin	Parabolic axial lighting device
US5866538A (en) *	1996-06-20	1999-02-02	Novo Nordisk A/S	Insulin preparations containing NaCl
ATE278711T1 (en) *	1996-07-11	2004-10-15	Novo Nordisk As	METHOD FOR SELECTIVE ACETYLATION
US5905140A (en) *	1996-07-11	1999-05-18	Novo Nordisk A/S, Novo Alle	Selective acylation method
US5763401A (en)	1996-07-12	1998-06-09	Bayer Corporation	Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
PT821006E (en) *	1996-07-26	2004-09-30	Aventis Pharma Gmbh	INSULIN DERIVATIVES WITH ENHANCED ZINC LINK
IL119029A0 (en)	1996-08-07	1996-11-14	Yeda Res & Dev	Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) *	1997-02-07	1999-04-27	Novo Nordisk A/S	Crystallization of proteins
CA2283705A1 (en) *	1997-03-20	1998-10-01	Novo Nordisk A/S	Zinc free insulin crystals for use in pulmonary compositions
ATE219942T1 (en)	1997-03-20	2002-07-15	Novo Nordisk As	THERAPEUTIC POWDER FORMULATION FOR PULMONARY USE CONTAINING CRYSTALLINE INSULIN
AU6611898A (en)	1997-03-20	1998-10-20	Novo Nordisk A/S	Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer
US7097845B2 (en)	1997-04-23	2006-08-29	Jacob Sten Petersen	Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
DK1283051T3 (en)	1997-06-13	2006-10-16	Lilly Co Eli	Stable insulin formulations
HUP0004169A3 (en)	1997-10-24	2001-06-28	Lilly Co Eli	Insoluble insulin compositions and process for production thereof
PL195845B1 (en) *	1997-10-24	2007-10-31	Novo Nordisk As	Aggregates of human insulin derivatives
US20020155994A1 (en) *	1997-10-24	2002-10-24	Svend Havelund	Aggregates of human insulin derivatives
US6451762B1 (en) *	1997-10-24	2002-09-17	Novo Nordisk A/S	Aggregates of human insulin derivatives
ZA989744B (en) *	1997-10-31	2000-04-26	Lilly Co Eli	Method for administering acylated insulin.
CO4970787A1 (en)	1997-12-23	2000-11-07	Lilly Co Eli	INSOLUBLE COMPOSITIONS OF INSULIN AND INSULIN DERIVATIVES THAT CONTROL BLOOD GLUCOSE
DE69924232D1 (en) *	1998-01-09	2005-04-21	Novo Nordisk As	STABILIZED INSULIN PREPARATIONS
US6211144B1 (en) *	1998-10-16	2001-04-03	Novo Nordisk A/S	Stable concentrated insulin preparations for pulmonary delivery
CN1210058C (en)	1998-10-16	2005-07-13	诺沃挪第克公司	Stable concentrated insulin preparations for pulmonary delivery
EP1820516B1 (en) *	1999-02-22	2013-07-24	University of Connecticut	Novel albumin-free factor VIII formulations
JP2002543092A (en)	1999-04-27	2002-12-17	イーライ・リリー・アンド・カンパニー	Insulin crystals for pulmonary administration
GB9930882D0 (en)	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
DE10022092A1 (en)	2000-05-08	2001-11-15	Aventis Behring Gmbh	Stabilized protein preparation and process for its preparation
US6652886B2 (en) *	2001-02-16	2003-11-25	Expression Genetics	Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (en) *	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinc-free and low-zinc insulin preparations with improved stability
ES2298378T3 (en)	2001-06-28	2008-05-16	Novo Nordisk A/S	STABLE FORMULATION OF MODIFIED GLP-1.
AU2002346490A1 (en)	2001-12-20	2003-07-09	Eli Lilly And Company	Insulin molecule having protracted time action
US8003605B2 (en) *	2002-03-13	2011-08-23	Novo Nordisk A/S	Minimising body weight gain in insulin treatment
WO2003094956A1 (en) *	2002-05-07	2003-11-20	Novo Nordisk A/S	Soluble formulations comprising monomeric insulin and acylated insulin
US20050232899A1 (en) *	2002-05-31	2005-10-20	Aradigm Corporation	Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) *	2002-06-20	2004-01-01	Bruce Kerwin	Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (en)	2002-08-23	2006-08-25	(주)헬릭서	Health food comprising the extract of Actinidia arguta and related species for the prevention and improvement of allergic disease and non-allergic inflammatory disease
JP2006504772A (en)	2002-10-29	2006-02-09	アルザ・コーポレーション	Stabilized solid polypeptide particles
US20040138099A1 (en) *	2002-11-29	2004-07-15	Draeger Eberhard Kurt	Insulin administration regimens for the treatment of subjects with diabetes
MXPA05008363A (en)	2003-02-07	2005-12-06	Ajinomoto Kk	Remedy for diabetes.
BRPI0407680A (en)	2003-02-19	2006-03-01	Novartis Ag	methods for cancer diagnosis and cancer cell metastasis reduction
WO2004078198A1 (en)	2003-03-04	2004-09-16	The Technology Development Company Ltd.	Long acting injectable insulin composition and methods of making and using thereof
ES2382157T3 (en)	2003-06-25	2012-06-05	Novo Nordisk Health Care Ag	Liquid composition of factor VII polypeptides
US20050054818A1 (en) *	2003-07-02	2005-03-10	Brader Mark Laurence	Crystalline compositions for controlling blood glucose
ES2472421T3 (en)	2003-08-05	2014-07-01	Novo Nordisk A/S	New insulin derivatives
AU2004261353B2 (en)	2003-08-05	2009-12-10	Novo Nordisk A/S	Novel insulin derivatives
EP1656158B1 (en)	2003-08-14	2016-03-09	Novo Nordisk Health Care AG	Liquid, aqueous pharmaceutical composition of factor vii polypeptides
WO2005021022A2 (en)	2003-09-01	2005-03-10	Novo Nordisk A/S	Stable formulations of peptides
ES2229931B1 (en) *	2003-10-03	2006-01-16	Grifols, S.A.	BILOGICALLY STABLE LIQUID COMPOSITION OF FVIII, FVW OR HUMAN FVIII / FVW COMPLEX.
EP1687428A1 (en) *	2003-11-14	2006-08-09	Novo Nordisk A/S	Processes for making acylated insulin
JP4845741B2 (en)	2003-12-23	2011-12-28	ファルマシアコーポレーション	Stable growth hormone liquid formulation
EP2106790B1 (en)	2004-03-12	2012-10-24	Biodel, Inc.	Rapid acting drug delivery compositions
EA012281B1 (en)	2004-06-01	2009-08-28	Арес Трейдинг С.А.	Method of stabilizing proteins
EP1796647B1 (en)	2004-08-12	2010-08-11	Schering Corporation	Stable pegylated interferon formulation
ES2395035T3 (en)	2004-08-17	2013-02-07	Regeneron Pharmaceuticals, Inc.	IL-1 antagonist formulations
ES2575984T3 (en)	2004-11-12	2016-07-04	Novo Nordisk A/S	Stable formulations of peptides containing an acylated GLP-1 analogue and a basal insulin
JP4874989B2 (en)	2004-11-22	2012-02-15	ノヴォノルディスクアー／エス	Soluble and stable insulin-containing formulation
AU2006206272A1 (en)	2005-01-21	2006-07-27	Alza Corporation	Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
WO2006082204A1 (en) *	2005-02-02	2006-08-10	Novo Nordisk A/S	Insulin derivatives
EP1969004B1 (en)	2005-12-28	2011-08-10	Novo Nordisk A/S	Compositions comprising an acylated insulin and zinc and method of making the said compositions
JP5202338B2 (en) *	2006-02-27	2013-06-05	ノボ・ノルデイスク・エー／エス	New insulin derivatives
WO2007121256A2 (en)	2006-04-12	2007-10-25	Biodel, Inc.	Rapid acting and long acting insulin combination formulations
AU2007247109B2 (en) *	2006-05-09	2012-03-15	Novo Nordisk A/S	Insulin derivative
JP5552046B2 (en) *	2007-06-13	2014-07-16	ノボ・ノルデイスク・エー／エス	Pharmaceutical preparation containing an insulin derivative
CN101861333A (en) *	2007-11-16	2010-10-13	诺沃-诺迪斯克有限公司	Pharmaceutical composition comprising a GLP-1 peptide or exendin-4 peptide and a basal insulin peptide
TWI451876B (en) *	2008-06-13	2014-09-11	Lilly Co Eli	Pegylated insulin lispro compounds

2004
- 2004-07-22 AU AU2004261353A patent/AU2004261353B2/en active Active
- 2004-07-22 WO PCT/DK2004/000511 patent/WO2005012347A2/en not_active Ceased
- 2004-07-22 PL PL09165072T patent/PL2107069T3/en unknown
- 2004-07-22 KR KR1020067002551A patent/KR101159559B1/en not_active Expired - Lifetime
- 2004-07-22 CA CA2531988A patent/CA2531988C/en not_active Expired - Fee Related
- 2004-07-22 BR BRPI0413276A patent/BRPI0413276B8/en active IP Right Grant
- 2004-07-22 EP EP09165072A patent/EP2107069B1/en not_active Expired - Lifetime
- 2004-07-22 MX MXPA06001283A patent/MXPA06001283A/en active IP Right Grant
- 2004-07-22 JP JP2006522233A patent/JP4463814B2/en not_active Expired - Lifetime
- 2004-07-22 EP EP04739008A patent/EP1660531A2/en not_active Withdrawn
- 2004-07-22 EP EP10174490.2A patent/EP2264065B1/en not_active Expired - Lifetime
2006
- 2006-01-05 IL IL172980A patent/IL172980A/en active Protection Beyond IP Right Term
- 2006-01-30 US US11/343,005 patent/US7615532B2/en active Active
- 2006-03-02 NO NO20061026A patent/NO340925B1/en active Protection Beyond IP Right Term
2008
- 2008-12-29 RU RU2008152033/04A patent/RU2518460C2/en active
2009
- 2009-09-16 US US12/560,833 patent/US8828923B2/en not_active Expired - Lifetime
2010
- 2010-02-10 AU AU2010200497A patent/AU2010200497B2/en active Active
2013
- 2013-03-28 CY CY20131100259T patent/CY1113850T1/en unknown
- 2013-06-10 LU LU92213C patent/LU92213I2/en unknown
- 2013-06-11 BE BE2013C035C patent/BE2013C035I2/fr unknown
- 2013-06-19 LU LU92226C patent/LU92226I2/en unknown
- 2013-06-19 BE BE2013C038C patent/BE2013C038I2/fr unknown
- 2013-07-04 CY CY2013027C patent/CY2013027PI1/en unknown
- 2013-07-04 FR FR13C0035C patent/FR13C0035I2/en active Active
- 2013-07-05 FR FR13C0038C patent/FR13C0038I1/en active Active
- 2013-07-08 CY CY2013029C patent/CY2013029PI2/en unknown
- 2013-07-18 HU HUS1300033C patent/HUS1300033I1/en unknown
2014
- 2014-08-06 US US14/453,276 patent/US20140349925A1/en not_active Abandoned
2018
- 2018-01-11 NO NO2018002C patent/NO2018002I2/en unknown
- 2018-01-11 NO NO2018003C patent/NO2018003I1/en unknown
2023
- 2023-12-28 CY CY2013029C patent/CY2013029I2/en unknown
2024
- 2024-01-16 NO NO2024003C patent/NO2024003I1/en unknown
- 2024-01-16 NO NO2024004C patent/NO2024004I1/en unknown
- 2024-01-31 CY CY2013027C patent/CY2013027I1/en unknown

Also Published As

Publication number	Publication date
NO2024004I1 (en)	2024-01-16
NO340925B1 (en)	2017-07-17
US7615532B2 (en)	2009-11-10
CY2013029PI1 (en)	2015-11-04
AU2004261353A1 (en)	2005-02-10
FR13C0035I2 (en)	2014-03-07
LU92213I2 (en)	2013-08-23
BE2013C035I2 (en)	2023-12-14
BRPI0413276A (en)	2006-10-10
JP4463814B2 (en)	2010-05-19
CY1113850T1 (en)	2015-11-04
US20100009899A1 (en)	2010-01-14
EP1660531A2 (en)	2006-05-31
NO2024003I1 (en)	2024-01-16
KR20060132543A (en)	2006-12-21
US20140349925A1 (en)	2014-11-27
CY2013027I2 (en)	2024-09-20
CY2013027PI2 (en)	2015-11-04
FR13C0035I1 (en)	2013-08-09
CA2531988C (en)	2016-06-28
NO2018002I1 (en)	2018-01-11
AU2004261353B2 (en)	2009-12-10
AU2010200497B2 (en)	2014-10-23
EP2107069A2 (en)	2009-10-07
NO20061026L (en)	2006-03-02
NO2018003I1 (en)	2018-01-11
FR13C0038I1 (en)	2013-08-09
CY2013029I1 (en)	2024-09-20
WO2005012347A2 (en)	2005-02-10
EP2107069B1 (en)	2013-01-16
US20060183668A1 (en)	2006-08-17
EP2264065A3 (en)	2011-07-27
BRPI0413276B1 (en)	2020-03-03
LU92213I9 (en)	2018-11-19
MXPA06001283A (en)	2006-04-11
KR101159559B1 (en)	2012-06-26
IL172980A (en)	2013-10-31
HUS1300033I1 (en)	2016-08-29
EP2264065A2 (en)	2010-12-22
WO2005012347A3 (en)	2005-04-14
RU2518460C2 (en)	2014-06-10
CY2013027PI1 (en)	2015-11-04
BRPI0413276B8 (en)	2021-05-25
BE2013C038I2 (en)	2023-12-14
CY2013027I1 (en)	2024-09-20
RU2008152033A (en)	2010-07-10
LU92226I9 (en)	2018-11-19
IL172980A0 (en)	2006-06-11
EP2107069A3 (en)	2009-11-25
CA2531988A1 (en)	2005-02-10
EP2264065B1 (en)	2017-03-08
NO2018002I2 (en)	2018-08-20
PL2107069T3 (en)	2013-06-28
LU92226I2 (en)	2015-04-29
JP2007523881A (en)	2007-08-23
CY2013029I2 (en)	2024-09-20
US8828923B2 (en)	2014-09-09
AU2010200497A1 (en)	2010-03-04

Publication	Publication Date	Title
CY2013027I2 (en)	2024-09-20	NEW INSULIN DERIVATIVES
DK1594840T3 (en)	2007-02-05	Piperidine-benzenesulfonamide derivatives
ATE352550T1 (en)	2007-02-15	CHINAZOLINE DERIVATIVES
CY2015036I1 (en)	2016-06-22	NEW OXAZOLIDINONE DERIVATIVES
ATE420066T1 (en)	2009-01-15	AMIDOACETONITRIL DERIVATIVES
DK2609947T3 (en)	2020-07-06	Plaster-like infusion set
IS8108A (en)	2005-10-31	New compounds
DE602004017700D1 (en)	2008-12-24	TRANSMUKOSEN ADMINISTRATION
ATE395345T1 (en)	2008-05-15	IMIDAZOLE-4-YL-ETHYNYL-PYRIDINE DERIVATIVES
IS2656B (en)	2010-08-15	New besimidasol derivatives
EP1661594A4 (en)	2010-04-14	SYRINGE
DK2107069T3 (en)	2013-04-15	New insulin derivatives
DE602004019555D1 (en)	2009-04-02	HETEROCYCLIC 7-AMINOALKYLIDENYLCHINOLONE AND -NAPHTHYRIDONE
IS8228A (en)	2006-01-11	New acetidine compounds
DK1682129T3 (en)	2007-06-11	N-thiazol-2-ylbenzamide derivatives
ATE449064T1 (en)	2009-12-15	AMIDOACETONITRIL DERIVATIVES
IS8292A (en)	2006-02-09	New compounds
IS8045A (en)	2005-09-26	Purin-6-one derivatives
FI20021817A0 (en)	2002-10-14	Cannula
UA6623S (en)	2002-11-15	SYRINGE
FI20030224A0 (en)	2003-02-13	New pharmaceutical uses
SE0301797D0 (en)	2003-06-19	New use V
SE0300106D0 (en)	2003-01-16	New use
SE0302332D0 (en)	2003-08-29	New use I
IS8301A (en)	2006-02-14	New Fusic Acid Derivatives